Hong Kong Investment Corporation Limited Publishes Annual Report 2024 (December 2025)
(Hong Kong, 4th December) The Hong Kong Investment Corporation Limited (“HKIC”) today released the Annual Report 2024, outlining the HKIC's investment and strategic positioning, and key progress.
As the Patient Capital investment institution established and wholly owned by the HKSAR Government, the HKIC carries the mission to invest for the future of Hong Kong with both financial and strategic dimensions. As of end October 2025, the HKIC has invested in over 150 projects across three key sectors, namely Hard and Core Technology, Biotech, and New Energy and Green Technology, as well as the relevant applications. Among the invested projects, two companies have already listed in Hong Kong, and over ten companies have either filed or planned to file their listing applications in Hong Kong this year. Every Hong Kong dollar invested by the HKIC has attracted over 6 Hong Kong dollars from long-term market capital.
Ms Clara Chan, Chief Executive Officer of the HKIC, said, “The HKIC is a professional institutional investor committed to long-term, value and responsible investing. Guided by our global perspective, the HKIC has been striving to enhance our influence in regional and international markets to contribute to the development of our nation, tell the Hong Kong stories, and facilitate the establishment of market rules and investable landscape that benefit all parties involved. At the same time, with the creation of the HKIC ecosystem, we have brought together resources and wisdom of both the public and private sectors in and beyond Hong Kong to drive the transformation, reshaping, and re-definition of new competitive edges of Hong Kong’s industrial, economic, and financial developments. In alignment with the development strategies of our nation and the long-term development needs for the prosperity of Hong Kong, the HKIC will continue to expand our strategic positioning and deepen collaboration with our investment partners.
As of end 2024, the capital invested by the HKIC accounted for less than one-fifth of our initial capital size, while generating more than HK$2.3 billion in investment income. Our investment strategy is progressive, aiming to cast the net wide enough before going deep into individual projects, with a view to striking a reasonable balance across multiple dimensions, namely capturing the window of opportunities for Hong Kong in a timely manner, seeking representation and voices at the regional and international tables, and managing investment risks, hence delivering both financial and strategic value. On the basis of the foundation built in 2024, the HKIC has further deepened and advanced our work in 2025, including injecting additional capital as planned to companies that met development and performance targets, such as leading their new financing rounds, in order to support them to seize market opportunities and ‘go global’.”
The full Annual Report 2024 has been uploaded to the HKIC website.
- END -
About HKIC
The HKIC was established in 2022 as the Patient Capital institution wholly owned by and representing the HKSAR Government. It adopts an “Investment +” approach, seeking reasonable financial return in the medium to long term and at the same time creating and supporting growth impetus with a view to contributing to Hong Kong’s economy and society.
The HKIC currently manages the “Hong Kong Growth Portfolio”, “Greater Bay Area Investment Fund”, “Strategic Tech Fund”, and “Co-Investment Fund”. At this stage, it is focusing on three key sectors, namely Hard and Core Technology, Biotech, and New Energy and Green Technology, as well as the relevant applications. As of end October 2025, the HKIC has invested in over 150 projects. Every Hong Kong dollar invested by the HKIC has attracted over 6 Hong Kong dollars from long-term capital for investment.